pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

8,883 catalysts · 6,552 phase readout · 2,325 8k filing · 388 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-17: 0 catalysts2026-08-18: 0 catalysts2026-08-19: 14 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout6,552
  • 8k filing2,325
  • earnings388
  • pdufa3
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Week of Aug 17, 2026

27
›Aug 18, 20268k filing2d ago$TTRX — Turn Therapeutics Inc. (TTRX) — 8-K filing

Items: 3.02

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$AMLX — Amylyx Pharmaceuticals, Inc. (AMLX) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$BMRN — BIOMARIN PHARMACEUTICAL INC (BMRN) — 8-K filing

Items: 1.01, 7.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$ONCY — ONCOLYTICS BIOTECH INC (ONCY) — 8-K filing

Items: 8.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$IRMD — IRADIMED CORP (IRMD) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$TNXP — Tonix Pharmaceuticals Holding Corp. (TNXP) — 8-K filing

Items: 5.02, 8.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$HALO — HALOZYME THERAPEUTICS, INC. (HALO) — 8-K filing

Items: 5.02

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$VREOF — Vireo Growth Inc. (VREOF) — 8-K filing

Items: 7.01, 8.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d agoLiminatus Pharma, Inc. (LIMN, LIMNW) — 8-K filing

Items: 3.01, 3.03, 5.03, 7.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$COCP — Cocrystal Pharma, Inc. (COCP) — 8-K filing

Items: 5.02, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$XAIR — Beyond Air, Inc. (XAIR) — 8-K filing

Items: 2.02, 7.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$AGEN — AGENUS INC (AGEN) — 8-K filing

Items: 1.01, 2.03, 3.02

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$TPST — Tempest Therapeutics, Inc. (TPST) — 8-K filing

Items: 5.07, 8.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$ABBV — AbbVie Inc. (ABBV) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$BAX — BAXTER INTERNATIONAL INC (BAX) — 8-K filing

Items: 1.01, 8.01, 9.01

full page →edgar 8k ↗
›Aug 18, 20268k filing2d ago$TCRX — TScan Therapeutics, Inc. (TCRX) — 8-K filing

Items: 1.02

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$SKYE — Skye Bioscience, Inc. (SKYE) — 8-K filing

Items: 3.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$TWST — Twist Bioscience Corp (TWST) — 8-K filing

Items: 7.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d agoKIORA PHARMACEUTICALS INC (KPRX, KPHMW) — 8-K filing

Items: 1.01, 7.01, 9.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$MNOV — MEDICINOVA INC (MNOV) — 8-K filing

Items: 5.02

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$MREO — Mereo BioPharma Group plc (MREO) — 8-K filing

Items: 3.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$BAX — BAXTER INTERNATIONAL INC (BAX) — 8-K filing

Items: 5.02, 7.01, 9.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$MMM — 3M CO (MMM) — 8-K filing

Items: 1.01, 1.02, 2.03

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$GCTK — Glucotrack, Inc. (GCTK) — 8-K filing

Items: 5.07

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$INBS — INTELLIGENT BIO SOLUTIONS INC. (INBS) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d ago$ETST — Earth Science Tech, Inc. (ETST) — 8-K filing

Items: 2.01, 7.01, 9.01

full page →edgar 8k ↗
›Aug 19, 20268k filing1d agoAspire Biopharma Holdings, Inc. (ASBP, ASBPW) — 8-K filing

Items: 7.01, 9.01

full page →edgar 8k ↗

Week of Jan 4, 2027

1
›Jan 4, 2027pdufa137dPDUFA — 2027-01-04

action date of January 4, 2027

full page →pdufa extract ↗

Week of Jan 18, 2027

1
›Jan 21, 2027pdufa154dPDUFA — 2027-01-21Ultragenyx Pharmaceutical Inc.

action date of Jan. 21, 2027

full page →pdufa extract ↗

Date TBD

21
›TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

full page →dexamethasone LA →fda approvals ↗
›TBDapprovalTRILEPTAL (OXCARBAZEPINE) — FDA approvalOXCARBAZEPINE

Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

full page →OXCARBAZEPINE →fda approvals ↗
›RECRUITINGphase readoutNCT06924671: GLA:D Back Canada - a Program for Chronic and Persistent Low Back Pain

Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain

full page →ctgov ↗
›COMPLETEDphase readoutNCT07542236: Hip and Ankle Mobility Rehabilitation for Soccer Players With Patellofemoral Pain

Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06941844: A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)Definium Therapeutics, Inc.

Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06466434: Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06806709: Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial)

Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection

full page →ctgov ↗
›RECRUITINGphase readoutNCT07178509: A Study of SCAD Using Stress Contrast EchocardiographyMayo Clinic

Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection

full page →ctgov ↗
›COMPLETEDphase readoutNCT07403409: Scapular Repeated Contractions Facilitation Versus Hold-relax Techniques in Patients With Adhesive Capsulitis

Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder

full page →ctgov ↗
›COMPLETEDphase readoutNCT06721663: Multisensory Environment Stimulation Therapy on Postural Control in Cerebral Palsy

Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06624787: Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07527221: Safety and Tolerability of ZE74-0282 in Healthy VolunteersCerta Therapeutics Pty Ltd

Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07329114: Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO)

Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections

full page →ctgov ↗
›RECRUITINGphase readoutNCT01778504: Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05103033: Systems Analysis and Improvement Approach to Optimize the Task-shared Mental Health Treatment Cascade (SAIA-MH)University of Washington

Sponsor: University of Washington. Phase: NA. Conditions: Mental Health Disorder

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT06906952: A Prospective Single-center Randomized Controlled Trial of Robotic Surgery With Transrectal Resection Specimens (NOSES-IV) and Traditional Assisted Robotic Surgery for the Treatment of High Rectal and Sigmoid Colon Cancer

Sponsor: Nanchang University. Phase: NA. Conditions: Natural Orifice Specimen Extraction Surgery, Robotic Surgery, Short-term Outcomes

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07281547: Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and PainMayo Clinic

Sponsor: Mayo Clinic. Phase: PHASE4. Conditions: Endometrial Carcinoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT07442149: An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005ALUMIS INC.

Sponsor: Alumis Inc. Phase: PHASE1. Conditions: Healthy Volunteer

full page →ctgov ↗
›COMPLETEDphase readoutNCT07418138: Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

Sponsor: Hu Liangshuo. Phase: . Conditions: Liver Transplantation, Hepatocellular Carcinoma (HCC), Tyrosine Kinase Inhibitor, Survival Rate

full page →ctgov ↗
›RECRUITINGphase readoutNCT07362238: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital

Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: PHASE2. Conditions: Immune Thrombocytopenia, Treatment

full page →ctgov ↗
›TERMINATEDphase readoutNCT04221438: Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementArray BioPharma Inc

Sponsor: ECOG-ACRIN Cancer Research Group. Phase: PHASE2. Conditions: Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma

full page →ctgov ↗
← prev
page 47 of 178
next →
$RARE26.39+3.53%
$ABBV258.92+3.43%
$DFTX46.18+2.03%
$ALMS24.88-2.43%
$NVS154.55+1.70%